Gilead Sciences Stock Investor Sentiment

GILD Stock  USD 90.49  0.30  0.33%   
About 61% of Gilead Sciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Gilead Sciences suggests that many traders are alarmed. The current market sentiment, together with Gilead Sciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Gilead Sciences stock news signals to limit their universe of possible portfolio assets.

Panic Vs Confidence

39

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Gilead Sciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Gilead Sciences.

Gilead Historical Sentiment

Although Gilead Sciences' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Gilead, such as negative comments on social media and news outlets, may cause fear in the market and push Gilead Sciences' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Gilead.
  

Gilead Sciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Gilead Sciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Gilead Sciences Historical Investor Sentiment

Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Gilead Sciences.
over a week ago at bizjournals.com         
Biotech giant Gilead Sciences to close its Seattle office, lay off employees
bizjournals News
over a week ago at seekingalpha.com         
Gilead Sciences prices 3.5B senior notes
seekingalpha News
over a week ago at kalkinemedia.com         
Gilead Sciences Announces Pricing of 3.5 Billion in Senior Unsecured Notes
news
over a week ago at businesswire.com         
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV G...
businesswire News
over a week ago at investing.com         
Gilead Sciences SWOT analysis stock outlook amid HIV dominance, pipeline progress
Investing News at Macroaxis
over a week ago at investing.com         
Citi sets 125 target on Gilead with Buy rating
Investing News at Macroaxis
over a week ago at seekingalpha.com         
Gilead reports positive HIV PrEP data for lenacapavir
seekingalpha News
over a week ago at finance.yahoo.com         
Gilead Sciences Soft Earnings Are Actually Better Than They Appear
Yahoo News
over a week ago at simplywall.st         
We Think You Can Look Beyond Gilead Sciences Lackluster Earnings
Simply Wall St News at Macroaxis
over a week ago at finance.yahoo.com         
AstraZeneca invests 3.5B in US manfacturing, RD
Yahoo News
over a week ago at express.co.uk         
The Handmaids Tale season 6 First look images released as show returns in 2025
news
over a week ago at gurufocus.com         
Decoding Gilead Sciences Inc A Strategic SWOT Insight
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Victory Capital Management Inc. Sells 468,814 Shares of Gilead Sciences, Inc.
news
over a week ago at zacks.com         
GILD or VRTX Which Is the Better Value Stock Right Now?
zacks News
over a week ago at businesswire.com         
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative H...
businesswire News
Far too much social signal, news, headlines, and media speculation about Gilead Sciences that are available to investors today. That information is available publicly through Gilead media outlets and privately through word of mouth or via Gilead internal channels. However, regardless of the origin, that massive amount of Gilead data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Gilead Sciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Gilead Sciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Gilead Sciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Gilead Sciences alpha.

Gilead Sciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
 
Gilead Sciences dividend paid on 27th of September 2024
09/27/2024
1
Gilead increases 2024 outlook, expects new drug filing by end of year
11/07/2024
2
Antibody-Drug Conjugates Technology Research and Global Markets Report 2021-2023 2024-2029 Increasing Cancer Incidences, Demand for Biologics, Innovations and C...
11/11/2024
3
Brokers Suggest Investing in Gilead Read This Before Placing a Bet
11/14/2024
4
Empower Advisory Group LLC Sells 3,420 Shares of Gilead Sciences, Inc.
11/15/2024
5
Gilead Sciences shares target upgraded, holds rating on HIV event outlook
11/18/2024
6
TOUCH, The Black Breast Cancer Alliance and Partners Launch the Black TNBC Sanctuary Resource Hub
11/19/2024
7
How Gilead Is Driving Global Health Equity And Innovation
11/20/2024
8
Gilead Sciences, Inc. Shares Sold by Tradewinds LLC.
11/21/2024
9
The Childrens Inn at NIH Announces 1 Million Grant From Gilead Sciences, Inc.
11/22/2024

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Commodity Directory
Find actively traded commodities issued by global exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals